Case Study

Operational & Strategic Excellence in Delivery of a Global Phase III Trial

Outcome: FDA Approval

Read more

In a milestone Alzheimer’s disease study for lecanemab, Worldwide encountered aggressive timeline expectations, multiple protocol amendments, and an unusual adverse event profile. Due to Worldwide’s adaptable, flexible approach, our teams still managed to deliver the study on time and on budget. See how our partnership with the sponsor led to study success.

Want to learn more about Worldwide Clinical Trials?